Carbapenems are one of the broad-spectrum groups of β-lactam antibiotics and have been considered the best choice for treatment of infections caused by multidrug-resistant bacteria,[@CIT0001] however, the recent increase in the rate of carbapenem resistance has been a cause for concern.[@CIT0002] Encoded by the *bla*~NDM-1~ gene, New Delhi metallo-β-lactamase 1 (NDM-1), one of the most active and transmissible carbapenemases among the carbapenem-hydrolyzing β-lactamases, was first characterized by Yong et al in 2009[@CIT0003] and has rapidly spread globally. To date, at least 17 NDM alleles have been characterized[@CIT0004] and the Tn*125* composite transposon bracketed by two copies of IS*Aba125* appears to be the main vehicle for dissemination of the *bla*~NDM-1~ gene.[@CIT0005] The lack of new generations of antibiotics has positioned colistin, a decades-old antibiotic, as one of the treatments of last resort against multidrug-resistant bacteria, particularly carbapenem-resistant Gram-negative bacteria.[@CIT0006],[@CIT0007] Unfortunately, colistin resistance has been reported and is increasing.[@CIT0008]--[@CIT0011]

*Enterobacter cloacae* belongs to the *Enterobacteriaceae* family. These Gram-negative bacteria have been a frequent cause of nosocomial multidrug-resistant bacterial infections in the last decade.[@CIT0012],[@CIT0013] Carbapenem-resistant *E. cloacae* has been commonly reported in Vietnam and many other countries in the world.[@CIT0014]--[@CIT0016] However, colistin resistance in *E. cloacae* has not been reported widely, particularly carbapenemase-producing colistin-resistant *E. cloacae* has very recently been reported from some countries including India,[@CIT0010] the United States,[@CIT0017] and China.[@CIT0018]--[@CIT0020]

In this study, the whole genome of a clinical carbapenem- and colistin-resistant *E. cloacae* strain, PIMB10EC27, was sequenced and analyzed for its genetic characteristics that may associate with its resistance phenotypes.

PIMB10EC27 was recovered from the urine of a 72-year-old male patient admitted to Binh Dan Hospital in Vietnam in December 2010 with diagnoses of invasive prostate cancer and urosepsis, he had undergone prostatectomy at the same hospital 15 days earlier. The patient was discharged at the request of the family in a state of acute urinary retention and respiratory failure 4 days after hospitalization. During hospitalization, the patient was treated with meropenem, cefoperazone, sulbactam, clavulanic acid, and amoxicillin, but not with colistin. The strain was isolated as a part of the routine hospital laboratory procedures and identified as *E. cloacae* using a Vitek II kit (BioMérieux, USA).

The in vitro antibiotic susceptibility of PIMB10EC27 was tested by the Kirby-Bauer (KB) method, and the minimum inhibitory concentration (MIC) using the agar dilution method was also determined according to recommendations of the Clinical and Laboratory Standards Institute (CLSI 2018)[@CIT0019] except for colistin, which was performed with broth microdilution method and interpreted by the guidelines of European Union Committee for Antimicrobial Susceptibility Testing (EUCAST 2019).[@CIT0020] The results showed that PIMB10EC27 was resistant to 21 of 26 tested antibiotics, particularly imipenem (MIC \>64 µg/mL), ertapenem (MIC =128 µg/mL), meropenem (MIC =128 µg/mL), and colistin (MIC \>128 µg/mL); susceptible to amikacin, levofloxacin nitrofurantoin; and showed intermediate resistance to ciprofloxacin, oxfloxacin ([Table 1](#T0001){ref-type="table"}).Table 1Antibiotic susceptibility of the *E. cloacae* PIMB10EC27AntibioticKirby-Bauer methodMIC (µg/mL)GentamycinRTobramycinRAmikacinS2KanamycinRPiperacillin-tazobactamRTicarcillin-clavulanic acidRImipenemR\>64ErtapenemR128MeropenemR128CefuroximeRCefotaximeR\>256CeftriaxoneR\>256CeftazidimeR\>256CiprofloxacinILevofloxacinSOfloxacinITrimethoprim-sulfamethoxazoleRSulfonamideRAztreonamRNitrofurantoinSPiperacillinRChloramphenicolR\>256TetracyclineR\>256DoxycyclineRCefoxitin\>256Colistin\>128[^1]

A Nextera XT DNA Library Prep Kit (Illumina Inc., USA) and SMRTbell Template Prep Kit (Pacific Biosciences, USA) were used to prepare libraries for the whole genome sequencing of PIMB10EC27 using simultaneously the MiSeq System (Illumina Inc.) with MiSeq Reagent Kit v.2 (2×150 cycles), and the PacBio RSII (Pacific Biosciences) together with Sequel Sequencing Kit 2.0 (8 rxn).

In total, 3.8Gb of filtered subreads were obtained from PacBio RSII sequencing platform. Using PacBio's pre-patching program, we obtained 353Mb of 35,932 reads with the sizes of 500--27,847 bp. The pre-assemble reads were further packaged with HGAP program, which yielded a 5,272,177 bp chromosome and two plasmids of 62,318 bp and 84,480 bp. MiSeq data was used for the error correction of PacBio consensus sequences. By integrating these two platforms, we were able to obtain the complete genome which consisted of a chromosome (5,272,177 bp) belonging to the ST513 group and two plasmids, pEC27-1 of the IncX3 group (62,470 bp) and pEC27-2 of the IncHI1 group (84,602 bp) ([Figure 1](#F0001){ref-type="fig"}). The complete genome sequence was annotated with NCBI Prokaryotic Genome Annotation Pipeline servers and analyzed by bioinformatics programs or software, including ResFinder 2.1,[@CIT0021] MLST,[@CIT0022] Isaga,[@CIT0023] Galaxy,[@CIT0024] and Plasmid Finder[@CIT0025] for antibiotic resistance genes identification, chromosome classification, sequences of insertion sequence (IS) determination, integrons finding, and plasmids classification, respectively. In total, 15 coding genes conferring resistance to 10 antibiotic groups were found on PIMB10EC27 ([Table 2](#T0002){ref-type="table"}). Among these genes, *bla*~NDM-1~, *bla*~SHV-12~, *bla*~CMH~,*aac~(3)-ID~, strA, strB, dfrA-14, sul2, catA2*, and *tet(D)* were associated with resistance phenotypes of PIMB10EC27.On the other hand *qnrS1* equivalent to the intermediate fluoroquinolone-resistance phenotype of PIMB10EC27 has been proven to reduce the antibiotic susceptibility of bacteria to quinolones or fluoroquinolone.[@CIT0026]--[@CIT0028] In addition, 160 putative transposase open reading frames (tORFs) were identified in which the number of tORFs located on the chromosome, pEC27-1 and pEC27-2 were 113, 10 and 37, respectively. Antibiotic resistance genes closely located to these transposase sequences may have contributed to the accumulation and increase in the antibiotic resistance of PIMB10EC27. A 1722-bp class 1 integron with gene cassette *dfrA14* flanked by IS6 sequences was also found on plasmid pEC27-2.Table 2Distribution of coding genes conferring to antibiotic resistance in PIMB10EC27GeneDescriptionResistance mechanismAntibiotic group/agent**Chromosome***bla*~CMH~CMH family class C β-lactamaseAntibiotic inactivationβ-lactams*fosA*FosA/FosA2 family fosfomycin resistance glutathione transferaseAntibiotic inactivationFosfomycin**pEC27-1***bla*~NDM-1~New Delhi metallo-β-lactamase NDM-1Antibiotic inactivationβ-lactams*bla*~SHV-12~Extended-spectrum beta-lactamase SHV-12Antibiotic inactivationβ-lactams*ble*~MBL~Bleomycin-resistance proteinSequestering effect of the bleomycin-binding proteinBleomycin**pEC27-2***aac(3)-IId*Aminoglycoside acetyltransferaseAntibiotic inactivationAminoglycosides*bla*~LAP-2~Class A β-lactamase LAP-2Antibiotic inactivationβ-lactams*bla*~TEM-1B~Class A broad-spectrum β-lactamase TEM-1Antibiotic inactivationβ-lactams*catA2*Chloramphenicol acetyltransferaseAntibiotic inactivationPhenicols*dfrA14*Dihydrofolate reductaseAltered affinity of reductaseTrimethoprim*qnrS1*Quinolone resistance pentapeptide repeat proteinAntibiotic target protectionQuinolones, fluoroquinolones*strA*Aminoglycoside phosphotransferaseAntibiotic inactivationAminoglycosides*strB*Aminoglycoside phosphotransferaseAntibiotic inactivationAminoglycosides*sul2*Sulfonamide resistant dihydropteroate synthaseAntibiotic target replacementSulphonamides*tet(D)*Tetracycline efflux pumpAntibiotic effluxTetracyclines Figure 1Structure of plasmid pEC27-1 and pEC27-2. pEC27-1 is an IncX3 plasmid that possesses highly syntenic plasmid backbone compare to IncHI1 plasmid pEC27-2. The outer circle shows ORFs on forward and reverse strands. Resistance genes, transposase genes and resolvase genes are depicted by red, black, blue arrows, respectively. The two inner circles show the GC content (purple circle) and GC skew (blue indicates positive values, red indicates negative values) information.

We further analyzed the genes in PIMB10EC27 that confer resistance to carbapenem and colistin. As a result, a *bla*~NDM-1~ gene was found on pEC27-1 of PIMB10EC27 along with a *bla*~SHV-12~ and *ble*~MBL~. A comparison of the nucleotide sequence of pEC27-1 and those of other IncX3 plasmids carrying *bla*~NDM-1~ and *bla*~SHV-12~, including pKPN5047 (KC311431), pNDM-HF727 (KF976405), pNDM-HN380 (JX104760), and RJA274 plasmid NDM-1 (KF877335) was carried out in order to identify if any unique structure characteristics contributed to the multidrug-resistance of PIMB10EC27. Comparative results of the genomic context surrounding the resistance genes revealed that all of the plasmids had a conserved sequence carrying ΔIS*Aba125, bla*~NDM-1~, *ble*~MBL~, *trpF, dsbC, cutA1, groES, groEL*, and IS*CR21* ([Figure 2](#F0002){ref-type="fig"}). This conserved sequence is also a Tn*125* composite transposon, in which the *bla*~NDM-1~ gene lies downstream of a truncated IS*Aba125* element that provides the −35 region for the promoter of *bla*~NDM-1.~[@CIT0029] A 93-bp sequence separates the right-hand inverted repeat of IS*Aba125* from the start codon of *bla*~NDM-1~, and the deletion of an IS*5* was identified in the plasmid pEC27-1. An IS*CR21*-like element was also found downstream of *bla*~NDM-1~ and it is suggested that this element may be responsible for initial gene capture.[@CIT0005] The IS26-bounded region of pEC27-1 containing *ygbI, ygbJ*, and *bla*~SHV-12~ was found to be very distinct from the other plasmids. This region carried three copies of IS*26*, and the local *ygbJ* gene was split into two parts, whereas other plasmids carried only two copies of IS26 and the full *ygbJ* gene. The isolation and reverse with a copy of IS*26* in the plasmid pEC27-1 of the 424-bp region of the *ygbJ* gene might propose there is an IS*26*-mediated re-organization. Interestingly, an insertion of IS*Kpn19* and Tn*6901* into the *mpr* gene (encoding zinc metalloproteinase) lying further upstream of *bla*~NDM-1~ was also observed ([Figure 2](#F0002){ref-type="fig"}). Belonging to IS*Kra4* family, IS*Kpn19* is 2851 bp in length and has been found to lie downstream of *bla*~OXA-181~ in an IncX3-type plasmid.[@CIT0030] Tn*6901*, first described in plasmid Rts1 of *Proteus vulgaris*,[@CIT0031] is 6.9 kb in length and harbors 6 genes, including a transposase gene (*tnpA*), a resolvase gene (*tnpR*), an alcohol dehydrogenase gene (*adh*), a glyoxalase/bleomycin resistance gene (*glo*), an S-formylglutathione hydrolase gene (*fgh*), and a regulatory protein gene (*frmR*). We report here the first case, to our knowledge, of a 9.8-kb insertion sequence harboring IS*Kpn19* and Tn*6901* in the genomic context of *bla*~NDM-1.~ This insertion made the genomic context of *bla*~NDM-1~ in PIMB10EC27 more complex with 6 resistance genes, including *adh, glo, fgh, bla*~NDM-1~, *ble*~MBL~, and *bla*~SHV-12,~ which may also affect the dissemination and expression of *bla*~NDM-1~. Further research is required to clarify these assumptions.Figure 2Genetic context of *bla*~NDM-1~ on IncX3 plasmids pKPN5047, pNDM-HF727, pNDM-HN380, RJA274 plasmid NDM-1, and pEC27-1. Gray shading denotes shared regions of homology: light gray indicates a forward match and dark gray indicates a reverse match. Notably, *ygbJ* is split into two parts, and the IS*26*-Δ*ygbJ* region is inverted in pEC27-1 relative to the other plasmids. The *mpr* gene in pEC27-1 is interrupted by IS*Kpn19* and Tn*6901* insertions. Open reading frames are portrayed by arrows and are colored. Resistance genes are indicated in red arrows, including *bla*~NDM-1~, *bla*~SHV-12~, *ble*~MBL~, *fgh, glo*, and *adh.*

Genome analysis was also performed to identify the genes that confer resistance to colistin of PIMB10EC27. In this research, we did not find any *mcr* gene that recently characterized as a novel mobile gene responsible for colistin resistance among Gram negative bacteria.[@CIT0032] In addition, our transformation experiments revealed that none of the plasmids of PIMB10EC27 was associated with colistin resistance (data not shown). In another context, encoding genes involved in the attachment of L-Ara-4N and P-EtN to LPSs of PIMB10EC27, including *phoP, phoQ, pmrB, pmrA, pmrC, mgrB, lpx*, and *arn* were examined, and amino acid replacements G273D in PmrB and F515S in PmrC of PIMB10EC27 were recorded. The role of these mutations in colistin resistance remains to be investigated.

In summary, we successfully constructed the complete genome of multidrug-resistant *E. cloacae* strain PIMB10EC27 carrying the novel genomic context of *bla*~NDM-1~. To our knowledge, this is the first report in Vietnam of a carbapenemase-producing *E. cloacae* strain that was also resistant to colistin. PIMB10EC27 was isolated from a patient not being treated with colistin and not identified as a case of a plasmid-mediated colistin-resistance mechanism.

In the battle against multidrug-resistant bacteria, particularly carbapenem-resistant bacteria, colistin has been considered to remain effective. In such context, this report of a clinical isolate that is resistant to both colistin and carbapenem raises a high concern over future clinical management and infection control.

**Nucleotide sequence accession numbers**. The complete nucleotide sequences of PIMB10EC27 have been deposited in GenBank under accession numbers CP020089-CP020091.

(<https://www.ncbi.nlm.nih.gov/nuccore/CP020089.1/>, <https://www.ncbi.nlm.nih.gov/nuccore/CP020090>, <https://www.ncbi.nlm.nih.gov/nuccore/CP020091>).
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[^1]: **Abbreviations**: R, Resistant; S, Sensitive; I, Intermediate.
